First-In-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR In Patients With Advanced Cancer

PURPOSE: To evaluate safety (primary endpoint), tolerability, pharmacokinetics, pharmacodynamic profile, and preliminary activity of the intravenous, pan-class I isoform PI3K/mTOR inhibitor PF-05212384 in patients with advanced solid tumors. EXPERIMENTAL DESIGN: Part 1 of this open-label phase I stu...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cancer Res
Hlavní autoři: Shapiro, Geoffrey I., Bell-McGuinn, Katherine M., Molina, Julian R., Bendell, Johanna C., Spicer, James, Kwak, Eunice L., Pandya, Susan, Millham, Robert, Borzillo, Gary, Pierce, Kristen, Han, Lixin, Houk, Brett, Gallo, Jorge D., Alsina, Maria, Braña, Irene, Tabernero, Josep
Médium: Artigo
Jazyk:Inglês
Vydáno: 2015
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4508327/
https://ncbi.nlm.nih.gov/pubmed/25652454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1306
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky